Sensitization of prostate cancer cell lines to 5-fluorocytosine induced by adenoviral vector carrying a CD transcription unit

被引:0
作者
Yin, LH [1 ]
Fu, SQ
Wang, XH
Nanakorn, T
Won, J
Deisseroth, A
机构
[1] Shanghai Med Univ, Dept Pathophysiol, Shanghai 200032, Peoples R China
[2] Yale Univ, Sch Med, New Haven, CT 06520 USA
[3] Cornell Univ, Sch Med, Ithaca, NY 14853 USA
关键词
cytosine deaminase; 5-fluorocytosine; gene therapy; prostate cancer;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To investigate the efficiency of the cytosine deaminase adenoviral/5-fluorocytosine system on prostate cancer cell lines. Methods We used cell culture, infectivity and sensitivity tests, to observe bystander effect by animal tests. Results Established prostate cancer cell lines are eventually infectible by adenoviral vector. The ratio of vector/cell at which infection occurs depends on the specific cell line. The peak of expression of the transferred cytosine deaminase gene occurred in cells at different time, but persisted beyond 11 days. These prostate cell lines are sensitized to 5-fluorocytosine by infection with adenoviral vector carrying the cytosine deaminase gene. Only 5% of the LNCap and 10% of the RM-1 cells were infected and produced 100% cell death. In the animal test, there was significant inhibition of tumor growth at a ratio of 400 vector particles/cell with the systematic treatment of 5-fluorocytosine. Conclusions Adenoviral vector carrying a cytosine deaminase transcription unit can sensitize prostate cancer cell lines to 5-fluorocytosine. The system can significantly inhibit the growth of prostatic tumors in mice.
引用
收藏
页码:972 / 975
页数:4
相关论文
共 9 条
[1]  
Gerber GS, 1996, JAMA-J AM MED ASSOC, V276, P615
[2]  
Hanna NN, 1997, CANCER RES, V57, P4205
[3]  
Hoganson DK, 1996, CANCER RES, V56, P1315
[4]  
HUBER BE, 1993, CANCER RES, V53, P4619
[5]  
Kuriyama S, 1998, ANTICANCER RES, V18, P3399
[6]  
MULLEN C, 1975, CHEMOTHERAPY, V21, P113
[7]   METABOLIC SUICIDE GENES IN GENE-THERAPY [J].
MULLEN, CA .
PHARMACOLOGY & THERAPEUTICS, 1994, 63 (02) :199-207
[8]  
Pederson LC, 1997, CANCER RES, V57, P4325
[9]  
Szary J, 1997, CANCER GENE THER, V4, P269